Results 181 to 190 of about 564,426 (377)

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada, Mary P. Choules, Frances A. Brightman, Shigeru Takeshita, Shinsuke Nakao, Nobuaki Amino, Takeshi Nakayama, Masato Takeuchi, Kanji Komatsu, Fernando Ortega, Hitesh Mistry, David Orrell, Christophe Chassagnole, Peter L. Bonate   +13 more
wiley   +1 more source

Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Efficacy and safety of ibrutinib 560 mg once daily or placebo combined with bendamustine and rituximab (BR) were assessed in patients with mantle cell lymphoma in a randomized phase 3 study (SHINE). The analysis described explores the ibrutinib population pharmacokinetics (PK) and exposure‐response (E‐R) relationships of selected efficacy and ...
Per Olsson Gisleskog, Belén Valenzuela, Nicoline Treijtel, Sanjay Deshpande, Todd Henninger, Juan José Perez‐Ruixo   +5 more
wiley   +1 more source

Can Burkitt's Lymphoma and Hodgkin's Lymphoma occur in siblings simultaneously?

The Turkish Journal of Pediatrics, 2015
Familial clustering of Hodgkin lymphoma (HL) and increased risk of developing disease among the siblings has been reported earlier. Usually familial lymphoma in sibling pairs occurs in the pairs of either non-Hodgkin lymphoma or HL.
Meriç Kaymak Cihan, Olcay Kandemir, Klara Dalva, Neriman Sarı, Nilgün Kurucu, İnci Ergürhan İlhan   +5 more
doaj  

Diffuse large B-cell lymphoma in the uterus with unexpected manifestations: a case report

Journal of Medical Case Reports
Background Lymphoid neoplasm is a common disease, arising from lymphoid cells. It is divided into Hodgkin lymphoma and non-Hodgkin lymphoma. Non-Hodgkin lymphoma can be intranodular or extranodular, which happens in 25% of primary cases.
Kenana Tawashi, Tuka Hamasho, Mustafa Al-Hussien, Ameen Ammar   +3 more
doaj   +1 more source

Malignancies and immunoglobulin G4‐related disease

Rheumatology &Autoimmunity, EarlyView.
Immunoglobulin G4‐related disease (IgG4‐RD) is associated with increased cancer risk. Malignancies affect both IgG4‐RD involved organs, such as the lung, pancreas, bile duct, and prostate, and noninvolved organs, such as the gastrointestinal duct. B‐cell neoplasms constitute a proportion of the malignancies linked to this disease.
Jingna Li, Wen Zhang
wiley   +1 more source

Diagnosis validity of AgNOR staining for differentaing non-Hodgkin lymphoma from reactive hyperplasia

مجله دانشگاه علوم پزشکی گرگان, 2005
Background&Objective: There are different methods including H&E, imonhistochemstry, flu cytometry, AgNOR staining for differentiation reactive hyperplasia from lymphoma.
Zh.Torabizade (MD), F.Naghshvar (MD), O.Emadian (MD)   +2 more
doaj  

Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells [PDF]

, 1996
Juergen Wolf, Ursula Kapp, Heribert Bohlen, Martin Kornacker, Claudia Schoch, Bernd Stahl, Susanne Mücke, Christof von Kalle, Christa Fonatsch, HE Schaefer, ML Hansmann, Volker Diehl   +11 more
openalex   +1 more source

Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape

Small, EarlyView.
This review presents a detailed overview of clinically approved nanoparticle therapeutics, classifying them by type and discussing their unique advantages in drug delivery. It highlights regulatory challenges across global markets and emphasizes the need for adaptive approval pathways.
Nimeet Desai, Dhwani Rana, Mitali Patel, Neha Bajwa, Rajendra Prasad, Lalitkumar K. Vora   +5 more
wiley   +1 more source

Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B- cell non-Hodgkin lymphoma [PDF]

, 1995
Bernd Hertenstein, Bettina Wagner, Donald Bunjes, C Duncker, A Raghavachar, Roland Arnold, H. Heimpel, Hubert Schrezenmeier   +7 more
openalex   +1 more source

Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in patients with non-Hodgkin's lymphoma in the United Kingdom (UK) [PDF]

Introduction: We report a cost-effectiveness evaluation of granulocyte colony-stimulating factors (G-CSFs) for prevention of febrile neutropenia (FN) following chemotherapy for non-Hodgkin’s lymphoma (NHL) in the United Kingdom (UK).
Akehurst, R, Cooper, KL, Stevenson, MD, Whyte, S   +3 more
core